GETH-TC

GETH-TC is an emerging biotechnology company specializing in the development of next-generation T-cell therapies for oncology. The company leverages a proprietary gene therapy platform to engineer T-cells with enhanced specificity and durability against both hematological and solid tumors. By focusing on advanced T-cell receptor (TCR) modifications, GETH-TC aims to overcome the current limitations of adoptive cell transfer, such as tumor microenvironment suppression and antigen escape. Their current pipeline is primarily in the pre-clinical stage, with several candidates undergoing optimization for clinical entry. GETH-TC represents a specialized player in the competitive landscape of engineered cell therapies, targeting high-unmet-need indications in the cancer space.